Evolus, Inc.
Moat Score — Evolus, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Owns U.S./EU regulatory approvals and marketing authorizations for Jeuveau and Evolysse and has built real brand recognition as the 'alternative to BOTOX,' but the underlying molecules/technology are licensed from Daewoong and Symatese rather than proprietary to Evolus. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | No manufacturing cost edge versus peers; margins are structurally worse than competitors' because of a mid-single-digit royalty owed to Medytox on net sales through September 2032. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Positioned as a value/alternative brand to BOTOX, which caps pricing power versus the category leader, though loyalty programs and co-branded marketing give some control over net pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Digital Practice App creates mild engagement effects among practitioners, but there is no real network effect since value does not scale with the number of users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Practitioner training, loyalty/rewards programs, and integrated ordering workflows create moderate stickiness, but practitioners can and do carry multiple competing brands simultaneously. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The medical aesthetics market is large, growing, and fragmented with multiple well-capitalized players; there is no natural scale ceiling limiting new entrants. |